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The effect of utilising granulocyte colony-stimulating factor (G-CSF) to maintain chemotherapy dose intensity in non-Hodgkin’s
lymphoma (NHL) on long-term mortality patterns has not been formally evaluated. We analysed prolonged follow-up data from the
first randomised controlled trial investigating this approach. Data on 10-year overall survival (OS), progression-free survival (PFS),
freedom from progression (FFP) and incidence of second malignancies were collected for 80 patients with aggressive subtypes of
NHL, who had been randomised to receive either VAPEC-B chemotherapy or VAPEC-BþG-CSF. Median follow-up was 15.7 years
for surviving patients. No significant differences were found in PFS or OS. However, 10-year FFP was better in the G-CSF arm (68 vs
47%, P¼0.037). Eleven deaths from causes unrelated to NHL or its treatment occurred in the G-CSF arm compared to five in
controls. More deaths occurred from second malignancies (4 vs 2) and cardiovascular causes (5 vs 0) in the G-CSF arm. Although this
pharmacovigilance study has insufficient statistical power to draw conclusions and is limited by the lack of data on smoking history and
other cardiovascular risk factors, these unique long-term outcome data generate hypotheses that warrant further investigation.
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One of the major dose-limiting toxicities of cytotoxic chemo-
therapy for non-Hodgkin’s lymphoma (NHL) is myelosuppression
and subsequent susceptibility to infection. Haemopoietic colony-
stimulating factors (G-CSF and GM-CSF) are now commonly
administered as an adjunct to cytotoxic chemotherapy in patients
with NHL, to reduce the incidence of these toxicities based on data
accrued from several randomised controlled studies (Pettengell
et al, 1992; Bastion et al, 1993; Gerhartz et al, 1993; Aviles et al,
1994; Engelhard et al, 1994; Gisselbrecht et al, 1997; Zinzani et al,
1997; Doorduijn et al, 2003; Osby et al, 2003). It has also been
suggested that CSF administration may improve overall survival
and cure rate in this population by both decreasing treatment-
related morbidity and, maintaining dose intensity, in accordance
with the Goldie and Coldman (1983) hypothesis.
Although a recent meta-analysis of the above studies and those
conducted in Hodgkin’s lymphoma (Bohlius et al, 2004) has
confirmed a 26% (95% CI 11–38%) reduction in the risk of febrile
neutropenia with CSF prophylaxis, no overall survival benefit was
noted despite a modest increase in the median cytotoxic dose
intensities achieved in the arms receiving CSFs being reported in
most studies.
However, the median follow-up of surviving patients in the trials
included in the meta-analysis was relatively short at 4.4 years
(range, 1.3–7.9 years) and all cause mortality was analysed. We
therefore decided to analyse long-term follow-up data from the
first published randomised study of G-CSF administration in NHL
patients (Pettengell et al, 1992) to determine whether the use of
G-CSF and consequent increase in chemotherapy dose intensity
will impact long-term survival, overall morbidity or the develop-
ment of unexpected late complications.
PATIENTS AND METHODS
Patients
Eighty patients aged 16–71 years with high-grade NHL (Kiel) of any
disease stage/performance status commencing VAPEC-B chemo-
therapy were entered between August 1989 and March 1991. Forty-
one were randomised to receive G-CSF (filgrastim (Amgen,
Thousand Oaks, CA, USA)-230mcgm
 2 by daily subcutaneous
injection for 13 weeks apart from days preceding and during
myelosuppressive chemotherapy administration) in addition to
chemotherapy and 39 received chemotherapy alone. Pretreatment
characteristics of the two groups were well matched for prognostic
factors (see Table 1). Thirty-four patients (83%) receiving G-CSF
and 29 (74%) in the control group completed chemotherapy.
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sPatients randomised to receive G-CSF achieved 12% greater
median dose intensity than control patients (95 vs 83%) – see
Table 1 for median dose intensities of adriamycin, cyclopho-
sphamide and etoposide.
Following completion of treatment, clinical details and disease
status were regularly updated in the trial database either from out
patient clinic annotations or by liaison with the patient’s primary
care physicians. Causes of death were retrieved from case notes or
death certification. The case notes of all patients who had died
since the previous publication or who had been designated as a
non-lymphoma death in the trial database were reviewed by two
authors (AC, JR).
Statistical methods
The objectives of the study were to evaluate the long-term effects of
the use of G-CSF and increased dose-intensity chemotherapy on
overall survival and mortality patterns. Definitions of reported end
points are as follows (Cheson et al, 2007).
Overall survival (OS) – time from randomisation to death from
any cause.
Freedom from progression (FFP) – time from randomisation to
first documentation of disease progression.
Progression-free survival (PFS) – time from randomisation to
the first of disease progression or death from any cause.
All analyses were performed on an intention-to-treat basis.
Kaplan and Meier, (1958) survival curves were drawn for overall
survival and progression-free survival and compared between the
treatment groups using the log-rank test. The proportions of
patients having experienced an event at 10 years were estimated
from the survival curves.
To assess the effects of specific causes of death, cumulative
incidence curves were constructed in a competing risks frame-
work. The cumulative incidence of death from cause x at time t is
the probability of dying from x by time t in an environment where
other causes of death are acting. The treatment groups were then
compared using Gray’s test (Gray, 1988).
A further analysis was also performed by fitting a multi-state
Cox illness/death model (Andersen et al, 1993) for the three
outcomes initial progression, death without progression and death
following progression. This formulation of the Cox regression
model allowed us to control for the potential effects of age, sex and
international prognostic index score (International Non-Hodgkin’s
lymphoma prognostic factors project, 1993).
Relative mortality models (Andersen et al, 1993) were estimated
for each trial arm separately using England and Wales death rates
broken down by sex, age (integer years) and period (annually up
until 2005, 2005 figures used for follow-up in 2006) obtained from
the Human Mortality database (2008).
RESULTS
Forty-eight of the eighty initial patients had died at the time of this
analysis. The median follow up of the 36 surviving patients was
15.7 years (range, 8.4–16.9 years). Of the 48 dead, 24 died in the
G-CSF arm and 24 in the control arm. Ten-year overall survival
figures were 51 and 46% in the G-CSF and control arms
respectively and 10-year PFS 49 and 44%.
The Kaplan–Meier survival curves for OS and FFP are
illustrated in Figure 1A and 1B respectively. Although OS and
PFS (data not shown) were virtually identical in both arms, FFP
was significantly higher in the interventional arm receiving G-CSF
and consequently 12% higher dose intensity of chemotherapy
(10-year FFP 68 and 47% for G-CSF and control arms respectively)
suggesting an imbalance in the causes of death between the two
arms. It was therefore decided to examine this in more detail and
these results are summarised in Table 2.
Eleven of 41 patients in the G-CSF arm had documented
progressive disease and 10 of these have subsequently died from
NHL. In the control arm, 21 of the 39 patients had disease
progression with 19 dying because of this (P¼0.02). The
cumulative incidence curves for lymphoma-specific death are
shown in Figure 1C. Paradoxically, 14 patients in the G-CSF arm
died from causes other than progressive NHL compared with five
in the control arm (P¼0.02) (Figure 1D).
To assess whether known lymphoma-related prognostic factors
may have influenced these findings, we controlled these using a
multi-state formulation of Cox regression model analysis (Table 3).
Age, sex, international prognostic index score and treatment arm
were analysed as separate variables. Unfortunately, baseline data
on known cardiovascular and second cancer risk factors for
example, smoking history, hypertension, serum cholesterol were
not routinely collected and so could not be included in this
analysis. However, the random allocation of patients to the two
treatment arms should allow for the equal distribution of these risk
factors between the two arms. This analysis confirmed that
patients receiving G-CSF were less likely to experience lymphoma
progression (HR 0.40; 95% CI 0.18–0.87) than controls but were
more likely to die prior to lymphoma progression (HR 3.08; 95%
CI 1.05–8.99).
Of the 14 non-NHL deaths in the G-CSF arm, three patients died
from treatment-related infections, two from neutropenic infections
during the 11-week treatment schedule and one from autopsy-
confirmed invasive aspergillosis 3 months after commencement of
Table 1 Patient characteristics at trial entry and dose intensity of
treatment received
G-CSF (n¼41) Control (n¼39)
Age (years)
Median (range) 51 (16–67) 53 (22–71)
Gender
Male 27 26
Female 14 13
ECOG PS
06 4
12 1 1 9
21 1 1 3
33 3
Disease stage
I9 8
II 12 14
III 5 3
IV 15 14
B symptoms 15 17
Histology (working formulation)
High 35 33
Intermediate 5 5
Unclassified 1 1
IPI risk grouping
Low 25 26
Low-intermediate 5 6
High-intermediate 6 2
High 5 5
Median dose intensity
Whole regimen 95% 83%
Adriamycin 96% 85%
Cyclophosphamide 96% 83%
Etoposide 94% 82%
ECOG PS¼Eastern Cooperative Oncology Group performance status.
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Figure 1 Survival end points. Survival curves comparing chemotherapy-alone arm (solid line) and chemotherapyþG-CSF arm (dashed line). Kaplan–
Meier plots for (A) overall survival (B) freedom from progression. Cumulative incidence curves for (C) NHL-specific death (D) non-NHL deaths (E) death
from causes other than progressive NHL and acute treatment-related infections (F) Deaths from second malignancy.
Table 2 Patient status at last follow-up
Patients
treated
Alive and
well (%)
Alive with
progressive
disease (%)
Dead from
NHL (%)
Dead from
treatment-related
infection (%)
Dead from
second
malignancy (%)
Dead from
other causes
(%)
Cause of death
not identified
(%)
G-CSF 41 17 (41) 0 10 (24) 3 (7) 4 (10) 6 (15) 1 (2)
Control 39 13 (33) 2 (5) 19 (46) 0 2 (5) 2 (5) 1 (3)
Median follow-up for surviving patients is 15.7 years (range, 8.4–16.9).
Table 3 Hazard ratio estimates (95% confidence interval) for three transitions in a multi-state cox illness/death model
Progression (n¼32/80) Death without progression (n¼18/80) Death following progression (n¼30/32)
Male vs female 1.07 (0.50, 2.29) P¼0.86 1.14 (0.41, 3.16) P¼0.80 0.99 (0.36, 2.71) P¼0.98
Age (years) 0.99 (0.96, 1.02) P¼0.51 1.13 (1.05, 1.21) P¼0.002 1.02 (0.98, 1.06) P¼0.34
IPI (integer score) 1.57 (1.23, 2.01) P¼0.0003 1.19 (0.84, 1.69) P¼0.34 1.38 (0.98, 1.94) P¼0.06
G-CSF vs control 0.40 (0.18, 0.87) P¼0.02 3.08 (1.05, 8.99) P¼0.04 0.69 (0.25, 1.85) P¼0.46
IPI¼international prognostic index. Significant hazard ratios are shown in bold.
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schemotherapy. No patient in the control arm died from treatment-
related infection.
Eleven deaths in the G-CSF arm and five in the control arms
were not due to NHL or treatment-related infection (P¼0.12)
(cumulative incidence curves Figure 1E). It was impossible to
assign a cause in two patients (one in each arm). Four patients who
received G-CSF died from second malignancies compared to two in
the control arm (Figure 1F). In total, second cancers were
documented in seven patients, five in the G-CSF arm and two in
the control arm. There were two cases of lung cancer (diagnosed 42
and 105 months after commencement of chemotherapy) and one
each of acute myeloid leukaemia (28 months), breast cancer (76
months) and disseminated cancer (131 months- no histological
diagnosis possible) in the G-CSF arm. In the control arm, two cases
of lung cancer (54 and 159 months) were diagnosed. One case of
localised cutaneous squamous cell carcinoma was also documen-
ted in the control arm.
Of the six other deaths in the G-CSF arm, five died from
cardiovascular disease (three myocardial infarctions, one
congestive cardiac failure and one ischaemic heart disease) and
one from an intracerebral haemorrhage. In the control arm, one
patient died from Pneumocystis carinii pneumonia 14 months
after chemotherapy with no evidence of recurrent NHL and one
from cirrhosis secondary to chronic hepatitis C infection. The
causes of non-lymphoma deaths are summarised in Table 4.
One possible explanation for these findings is that because
patients who were exposed to G-CSF appeared less likely to
experience progression of lymphoma, they were exposed to other
competing causes of death for longer than patients who did not
receive G-CSF but with the proportional rate of non-lymphoma-
related mortality being the same in both groups. To assess this
possibility, we constructed relative mortality models for each trial
arm separately using England and Wales death rates broken down
by sex, age (integer years) and period (annually up until 2005, 2005
figures used for follow-up in 2006) obtained from the Human
Mortality Database (Figure 2). This analysis tentatively indicates
that after the period of early excess relative mortality associated
primarily with lymphoma-related events, the relative mortality rate
in the surviving subjects appears somewhat higher in the G-CSF
treated subjects than in those who received chemotherapy alone.
DISCUSSION
There have been numerous randomised studies on the use of
G-CSF during induction chemotherapy for high-grade NHLs
(Pettengell et al, 1992; Bastion et al, 1993; Gerhartz et al, 1993;
Aviles et al, 1994; Engelhard et al, 1994; Gisselbrecht et al, 1997;
Zinzani et al, 1997; Doorduijn et al, 2003; Osby et al, 2003). While a
recent meta-analysis (Bohlius et al, 2004) of these indicates a
clinical benefit in terms of reducing the risk of febrile neutropenia,
no clear improvement was demonstrable in terms of tumour
response or survival parameters. However, follow-up was short
(median 4.4 years) and cause-specific survival was not analysed.
In this report, we detail long-term pharmacovigilance follow up
of the first randomised study of G-CSF during induction
chemotherapy for high-grade NHL (Pettengell et al, 1992). No
such extended follow-up has previously been presented. While
progression-free and overall survival figures were similar in the
cohort of patients receiving G-CSF and those in the control arm
(Table 1), a difference was noted in the percentage of patients free
from lymphoma progression at 10 years (68% G-CSF intervention
arm vs 47% control arm). This prompted us to further investigate
the mortality patterns of the two study groups, which were well-
balanced at original randomisation for age, sex and performance
status (Table 1). Nineteen patients in the control group died from
progressive NHL compared with 10 in the G-CSF group (P¼0.02)
while five died from other causes in the control group compared
with 14 in the G-CSF group (P¼0.02). Despite the small size and
retrospective nature of our analysis, this observation could support
the hypothesis that the use of G-CSF to facilitate chemotherapy
administration allows greater lymphoma-specific survival at the
expense of death from other causes. However, our analysis is
limited by the lack of baseline information on major risk factors
for both second malignancies and cardiovascular disease including
smoking and family histories, hypertension, diabetes and choles-
terol levels. The random allocation of patients to treatment arm
will have limited uneven distribution of these variables between
the two treatment arms but we cannot exclude biased distribution
as an explanation of our findings.
An excess of deaths from acute treatment-related infective
complications were noted in the intervention arm of our study.
The reasons for this are unclear. Identical cytotoxic dose
modification criteria were applied in both groups and G-CSF
administration reduced the risk of febrile neutropenia. No
Table 4 Causes of non-lymphoma deaths
G-CSF Control
Cause
TTD
(mos) Cause
TTD
(mos)
Second cancer
AML 28 NSCLC 154
NSCLC 48 NSCLC 165
NSCLC 104
Metastatic carcinoma 131
Cardiovascular disease
MI 2
MI 3.5
Cardiac failure 115
MI 134
IHD 192
Other
Intracerebral haemorrhage 3 Not known 6.5
Not known 92 PCP 14
Cirrhosis secondary
to Hepatitis C
182
AML¼acute myeloid leukaemia; IHD¼ischaemic heart disease; MI¼myocardial
infarction; NSCLC¼Non-small cell lung cancer; PCP¼pneumocystis carinii
pneumonia. Deaths from treatment-related infections are not included.
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Figure 2 Relative mortality models. Relative mortality functions were
estimated for each trial arm separately. While relative mortality rates in the
chemotherapy alone arm return close to the underlying population with
continued follow-up (slope gradient close to 1), rates appear to remain
somewhat higher in the G-CSF treated arm.
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sincreased on-chemotherapy mortality was seen associated with
G-CSF administration in the Bohlius meta-analysis (relative
risk– 0.93 95% CI 0.60–1.43) (Bohlius et al, 2004).
Eleven patients died from other causes in the G-CSF arm
compared with five in the control arm (P¼0.12). The occurrence
of deaths from second malignancy and cardiovascular disease
which account for the majority of these (9; G-CSF vs 2; control) are
of particular interest as it is now apparent from large epidemio-
logic analyses of NHL databases that long-term NHL survivors are
at increased risk from these treatment-related complications.
Second malignancy
An increased incidence of second malignancy has been reported in
most but not all retrospective cohort studies (Travis et al, 1993;
Andre ´ et al, 2004; Moser et al, 2006a; Mudie et al, 2006). Although
Andre ´ et al (2004) failed to demonstrate an overall increased risk
of second cancer after a median follow-up of 74 months in 2837
patients with NHL treated with adriamycin-cyclophosphamide-
vindesine–bleomycin–prednisolone, they noted an excess of
myeloid malignancies and an increased risk of lung cancer in
males. Other studies have demonstrated a 20–30% overall
increased incidence of malignancy primarily due to increased
rates of leukaemia, lung and possibly colorectal cancers (Travis
et al, 1993; Moser et al, 2006a; Mudie et al, 2006). It is also
apparent that this elevated risk persists for at least 15 years after
NHL treatment and is inversely related to age at diagnosis.
There are several studies that suggest that the use of G-CSF may
increase the risk of secondary myeloid malignancies during follow-
up (Relling et al, 2003; Hershman et al, 2007) however, evidence
from NHL studies are lacking. G-CSF to facilitate dose dense
chemotherapy (two vs three weekly CHOP) in the first-line therapy
of aggressive NHL (Pfreundschuh et al, 2004a,b) improved 5-year
event-free and overall survivals without any significant increase in
the incidence of second cancers in the dose dense treatment arms
after 58 months median follow-up. The total dose of chemotherapy
delivered was identical in both arms and it is possible that follow-
up in these studies is not yet long enough to detect any differences.
Although increased dose intensity may be postulated as one
contributory factor to an increase in the incidence of second
malignancies in patients exposed to G-CSF in this study,
experimental studies have implicated a mechanistic role for CSFs
in the potentiation of neoplastic progression. CSFs have been
implicated as direct promoters of both tumour cell growth and
migration (Mueller et al, 1999; Obermuller et al, 2004) and have
also been shown to have paracrine as well as autocrine tumour
promoting properties as they modulate the tumour stroma and
enhance angiogenesis in a squamous skin carcinoma model
(Obermuller et al, 2004).
Cardiovascular disease
Although the long-term risk of cardiovascular disease in patients
treated for aggressive NHL has not been extensively investigated,
an increased incidence of chronic heart failure (SIR 5.4, 95% CIs
4.1–6.9) has been reported in one retrospective cohort study of
592 patients (Moser et al, 2006b). Although no overall increase in
myocardial infarction was noted, the risk was elevated in patients
with at least 5 years follow-up. This is consistent with data from
the Collaborative British Cohort Study in Hodgkin’s disease
(Swerdlow et al, 2007), which noted increased risks of myocardial
infarction associated with anthracycline and vincristine-containing
chemotherapy regimens that were significant even in the absence
of supradiaphragmatic radiotherapy.
How G-CSF could affect the long-term incidence of cardiovas-
cular disease is less clear. Although patients receiving G-CSF
achieved a 12% increased adriamycin dose intensity, total dose
(200mgm
 2) was still well below the conventional ceiling dose for
clinically apparent cardiotoxicity of 400–450mgm
 2. It is also
intriguing to note that G-CSF appears to protect from anthracy-
cline cardiomyopathy in animal models (Hou et al, 2006) and has
been proposed as a possible preventive agent in the clinic
(Takemura and Fujiwara, 2007).
To conclude, this unique long-term follow-up data of the first
randomised study investigating the use of G-CSF in the first-line
chemotherapeutic treatment of high-grade NHL suggests that
although overall survival is not altered by this intervention, the
pattern of mortality may be changed. Although potential long-term
increased risk of second malignancy and cardiovascular disease in
patients receiving G-CSF is intriguing and may have significant
implications, the small size of the original study cohorts, lack of
information on other known risk factors and the post hoc nature of
this analysis limits the conclusions that can be drawn. However,
this analysis emphasises the need for long-term and detailed
follow-up of patients enrolled into such studies and the sharing of
these data for the purposes of meta-analysis.
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